Gout
BEMER for Gout
Supporting uric acid clearance, circulation, and joint recovery.
About this condition
Gout is the most common form of inflammatory arthritis, affecting an estimated 3–4% of adults. It is caused by hyperuricaemia — elevated uric acid in the blood — which leads to the deposition of monosodium urate crystals in joints, tendons, and surrounding tissue. The result is sudden, intensely painful joint inflammation, most commonly in the big toe, ankles, and knees. Gout is not simply a dietary condition — the primary driver in most patients is impaired uric acid excretion through the kidneys, a process directly linked to microcirculatory health and renal blood flow. Poor peripheral circulation also impairs the clearance of urate crystals from joint tissue during and after acute attacks. BEMER addresses gout from this vascular angle.
How BEMER helps
The kidney's ability to filter and excrete uric acid depends on adequate renal blood flow. When microcirculation is impaired — as it commonly is in people with gout, who frequently also have metabolic syndrome, hypertension, and diabetes — renal uric acid clearance is reduced. In the affected joint, post-attack recovery depends entirely on microcirculatory flow to clear inflammatory debris, including residual urate crystals. Poor peripheral circulation — particularly in the distal extremities where gout most commonly strikes — creates exactly the conditions in which urate crystals accumulate and persist: poor blood flow, lower tissue temperature, and reduced urate solubility. BEMER improves microcirculatory flow throughout the body, including peripheral extremities, supporting both systemic uric acid clearance and local joint recovery after acute attacks.
Key benefits
Important to know
BEMER is not recommended directly on an acutely inflamed joint during the height of a gout attack. The affected joint is typically too painful and sensitive. BEMER can be used on other body areas during an acute attack. Once the acute inflammation begins to subside — usually after 3–5 days with appropriate medication — gentle use on the recovering joint can begin. BEMER does not lower serum uric acid and does not replace urate-lowering therapy (allopurinol, febuxostat). It is a vascular support tool used alongside medical management.
Please note: Research on PEMF therapy in inflammatory arthritis demonstrates anti-inflammatory effects, pain reduction, and improved joint function. The specific mechanism relevant to gout — improved microcirculatory clearance — is supported by BEMER's extensive vasomotion research conducted by the Institute for Microcirculation (IfM) in Berlin.